Log In
BCIQ
Print this Print this
 

AMG 301

  Manage Alerts
Collapse Summary General Information
Company Amgen Inc.
Description mAb targeting adenylate cyclase activating polypeptide 1 pituitary receptor type I (ADCYAP1R1; PAC1)
Molecular Target Adenylate cyclase activating polypeptide 1 pituitary receptor type I (ADCYAP1R1) (PAC1)
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPhase I
Standard IndicationMigraine
Indication DetailsTreat migraines
Regulatory Designation
PartnerNovartis AG

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

0

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

09/01/2015

Undisclosed

Undisclosed

Undisclosed

Get a free BioCentury trial today